Paul Watkins

Paul Watkins serves as the Howard Q. Ferguson Distinguished Professor in the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill, where he leads research in the Molecular Therapeutics program. His work focuses on molecular mechanisms of drug disposition with critical applications in oncology pharmacology and drug safety assessment.

His research expertise spans:

• Drug metabolism and pharmacokinetics
• Drug transporter biology (particularly P-glycoprotein)
• Mechanisms of drug-induced liver injury (DILI)
• Quantitative systems toxicology modeling
• Clinical translation of pharmacological principles
• Genetic determinants of drug response variability

Analysis of his recent publications (2023-2025) reveals a sustained focus on DILI mechanisms through quantitative systems toxicology approaches. His team develops and applies computational models like DILIsym to predict hepatotoxicity, assess genetic risk factors, and evaluate safety of novel therapeutics including gene therapies and targeted cancer agents. Key trends include biomarker discovery, species-specific toxicity modeling, and risk mitigation strategies for drugs with narrow therapeutic windows.

Professional recognition includes:

• Howard Q. Ferguson Distinguished Professorship

Dr. Watkins directs a highly collaborative research program funded by NIH and industry partners, focusing on drug safety science. His mentorship has trained numerous graduate students and postdoctoral fellows who now contribute to pharmaceutical development and regulatory science. Current projects integrate genomic data with mechanistic modeling to predict individual susceptibility to adverse drug reactions.

His laboratory at 311 Pharmacy Lane employs multidisciplinary approaches spanning molecular pharmacology, clinical data analysis, and computational modeling to address critical challenges in drug development and patient safety.